Are we making the right choices to bring new drugs to the marketplace?
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Antibiotic effect and microbiome persistence vary along the European seabass gut
Scientific Reports Open Access 19 June 2020
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Projan, S. J. Curr. Opin. Microbiol. 6, 427–430 (2003).
Wenzel, R. P. N. Engl. J. Med. 351, 523–526 (2004).
Infectious Diseases Society of America. Bad Bugs, No Drugs; http://www.idsociety.org/Template.cfm?Section=Home&CONTENTID=7455&TEMPLATE=/ContentManagement/ContentDisplay.cfm (2004).
Centers for Disease Control and Prevention. A Public Health Action Plan to Combat Antimicrobial Resistance; http://www.cdc.gov/drugresistance/actionplan/html/index.htm (2000).
Coates, A., Hu, Y., Bax, R. & Page, C. Nature Rev. Drug Discov. 1, 895–910 (2002).
World Health Organization Draft Global Strategy for the Containment of Antimicrobial Resistance; http://www.who.int/emc/amr.html (2001).
Service, R. F. Science 303, 1796–1799 (2004).
Walsh, C. Nature Rev. Microbiol. 1, 65–70 (2003).
Miesel, L., Greene, J. & Black, T. A. Nature Rev. Genet. 4, 442–456 (2003).
Global Alliance for Tuberculosis Drug Development. The Economics of TB Drug Development; http://www.tballiance.org/pdf/Economics%20Report%20Full%20(final).pdf (2001).
Chopra, I., Hodgson, J., Metcalf, B. & Poste, G. J. Am. Med. Assoc. 275, 401–403 (1996).
Darwin, K. H., Ehrt, S., Gutierrez-Ramos, J. C., Weich, N. & Nathan, C. F. Science 302, 1963–1966 (2003).
Bryk, R., Lima, C. D., Erdjument-Bromage, H., Tempst, P. & Nathan, C. Science 295, 1073–1077 (2002).
Schnappinger, D. et al. J. Exp. Med. 198, 693–704 (2003).
Sassetti, C. M., Boyd, D. H. & Rubin, E. J. Mol. Microbiol. 48, 77–84 (2003).
Tong, A. H. et al. Science 303, 808–813 (2004).
Fidock, D. A., Rosenthal, P. J., Croft, S. L., Brun, R. & Nwaka, S. Nature Rev. Drug Discov. 3, 509–520 (2004).
Manetsch, R. et al. J. Amer. Chem. Soc. 126, 12809–12819(2004).
Keller, M. & Zengler, K. Nature Rev. Microbiol. 2, 141–150 (2004).
Liu, J. et al. Nature Biotechnol. 22, 185–191 (2004).
Nwaka, S. & Ridley, R. G. Nature Rev. Drug Discov. 2, 919–928 (2003).
Vennerstrom, J. L. et al. Nature 430, 900–904 (2004).
World Health Organization, Commisssion on Macroeconomics and Health Macroeconomics and Health: Investing in Health for Economic Development; http://www.cmhealth.org (2001).
Acknowledgements
Thanks to A. Apt, K. Deitsch, H. Djaballah, B. Ganem, W. Jorgensen, T. Kapoor, M. MacCoss, V. Mizrahi, S. Projan, L. Quadri, K. Rhee, M. Rosenberg, D. Russell, D. Scheinberg, D. Schnappinger, D. Tan, T. Templeton and P. van Helden for stimulating discussions. Special thanks are due to P. Davies, S. Ehrt, M. Glickman, B. Kelly, J. McKinney and S. Nwaka.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Nathan, C. Antibiotics at the crossroads. Nature 431, 899–902 (2004). https://doi.org/10.1038/431899a
Published:
Issue Date:
DOI: https://doi.org/10.1038/431899a